$HRGN
Harvard Apparatus Regenerative Technology Inc

2019 Q2 Form 10-Q Financial Statement

#000114420419025987 Filed on May 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.310M $1.000M $952.0K
YoY Change 18.55% 7.76% -1.86%
% of Gross Profit
Research & Development $1.358M $1.034M $1.148M
YoY Change 46.34% 87.32% 144.26%
% of Gross Profit
Depreciation & Amortization $54.00K $61.00K $67.00K
YoY Change -22.86% -3.17% -16.25%
% of Gross Profit
Operating Expenses $2.668M $2.034M $2.100M
YoY Change 31.23% 37.43% 45.83%
Operating Profit -$2.034M
YoY Change 37.43%
Interest Expense $89.00K
YoY Change -72.19%
% of Operating Profit
Other Income/Expense, Net $239.0K $107.0K $176.0K
YoY Change -985.19% -264.62% -260.0%
Pretax Income -$2.429M -$1.927M -$1.835M
YoY Change 17.91% 24.72% 49.19%
Income Tax
% Of Pretax Income
Net Earnings -$2.429M -$1.927M -$1.835M
YoY Change 17.91% 24.72% 49.19%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$368.5K -$321.0K -$322.8K
COMMON SHARES
Basic Shares Outstanding 6.672M 6.170M 5.669M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.251M $1.065M $1.305M
YoY Change -78.47% -62.23% -67.7%
Cash & Equivalents $1.115M $1.355M
Short-Term Investments
Other Short-Term Assets $566.0K $549.0K $90.00K
YoY Change 1472.22% 1425.0% -15.09%
Inventory
Prepaid Expenses
Receivables $223.0K $114.0K $176.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.040M $1.728M $2.154M
YoY Change -67.08% -47.16% -51.19%
LONG-TERM ASSETS
Property, Plant & Equipment $596.0K $466.0K $479.0K
YoY Change 4.01% -21.02% -24.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $596.0K $609.0K $479.0K
YoY Change 4.01% 3.22% -24.21%
TOTAL ASSETS
Total Short-Term Assets $2.040M $1.728M $2.154M
Total Long-Term Assets $596.0K $609.0K $479.0K
Total Assets $2.636M $2.337M $2.633M
YoY Change -61.06% -39.46% -47.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $251.0K $311.0K $160.0K
YoY Change 50.3% 29.58% -82.67%
Accrued Expenses $555.0K $540.0K $404.0K
YoY Change -42.19% 25.58% 6.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $895.0K $956.0K $662.0K
YoY Change -34.34% 18.17% -59.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $25.00K $44.00K $0.00
YoY Change
Total Long-Term Liabilities $25.00K $44.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $895.0K $956.0K $662.0K
Total Long-Term Liabilities $25.00K $44.00K $0.00
Total Liabilities $920.0K $1.000M $662.0K
YoY Change -32.5% 23.61% -59.19%
SHAREHOLDERS EQUITY
Retained Earnings -$57.69M -$55.76M
YoY Change 15.89% 15.61%
Common Stock $62.00K $57.00K
YoY Change 113.79% 128.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.716M $1.337M $1.971M
YoY Change
Total Liabilities & Shareholders Equity $2.636M $2.337M $2.633M
YoY Change -61.06% -39.41% -47.81%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$2.429M -$1.927M -$1.835M
YoY Change 17.91% 24.72% 49.19%
Depreciation, Depletion And Amortization $54.00K $61.00K $67.00K
YoY Change -22.86% -3.17% -16.25%
Cash From Operating Activities -$2.037M -$1.216M -$2.184M
YoY Change 74.1% -40.97% 32.36%
INVESTING ACTIVITIES
Capital Expenditures -$54.00K $24.00K -$4.000K
YoY Change -40.0% 700.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$54.00K -$24.00K -$4.000K
YoY Change -32.5% -152.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.277M 1.000M 0.000
YoY Change -46.04% 25.79% -100.0%
NET CHANGE
Cash From Operating Activities -2.037M -1.216M -2.184M
Cash From Investing Activities -54.00K -24.00K -4.000K
Cash From Financing Activities 2.277M 1.000M 0.000
Net Change In Cash 186.0K -240.0K -2.188M
YoY Change -93.74% -80.31% -180.15%
FREE CASH FLOW
Cash From Operating Activities -$2.037M -$1.216M -$2.184M
Capital Expenditures -$54.00K $24.00K -$4.000K
Free Cash Flow -$1.983M -$1.240M -$2.180M
YoY Change 83.61% -39.89% 32.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
441000
CY2018Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
404000
CY2018Q1 us-gaap Revenues
Revenues
0
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
623000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
1728000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
2154000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
466000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
479000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2633000
CY2019Q1 us-gaap Assets
Assets
2337000
CY2018Q4 us-gaap Assets
Assets
2633000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
311000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
160000
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2019Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
114000
CY2018Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
176000
CY2019Q1 us-gaap Revenues
Revenues
0
CY2019Q1 us-gaap Cash
Cash
1065000
CY2018Q4 us-gaap Cash
Cash
1305000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
499000
CY2019Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
105000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
98000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
956000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
662000
CY2019Q1 us-gaap Liabilities
Liabilities
1000000
CY2018Q4 us-gaap Liabilities
Liabilities
662000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
62000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
57000
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58965000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57677000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57690000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55763000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1337000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1971000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2337000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1034000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
552000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1000000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
928000
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7000
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
124000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6003000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2751000
CY2019Q1 bstg Grant Income
GrantIncome
114000
CY2018Q1 bstg Grant Income
GrantIncome
59000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1545000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
293000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
75000
CY2019Q1 us-gaap Depreciation
Depreciation
61000
CY2018Q1 us-gaap Depreciation
Depreciation
63000
CY2019Q1 bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
7000
CY2018Q1 bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
124000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-124000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
67000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
127000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-698000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
37000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
47000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1216000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2060000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46000
CY2019Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2018Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1095000
CY2019Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1000000
CY2018Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
795000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-240000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1219000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1355000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4038000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1115000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2819000
CY2019Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
24000
CY2018Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
14000
CY2019Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-62000
CY2018Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
59000
CY2019Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2018Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
49000
CY2018Q1 bstg Maximum Research And Development Expenses Reimbursement
MaximumResearchAndDevelopmentExpensesReimbursement
225000
CY2018Q4 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
On October 26, 2018, the Company was awarded Phase II of the SBIR grant for $1.1 million to support development, testing, and translation to the clinic through September 2019. The Phase II grant includes an additional $0.5 million for future period support through September 2020, subject to availability of funding and satisfactory progress on the project. Accordingly, the SBIR grant has the potential to provide a total award of $1.8 million.
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
50000
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
105000
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
50000
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
98000
CY2017Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
300000
CY2019Q1 bstg Product Distribution Agreement Term
ProductDistributionAgreementTerm
P10Y
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5669645
CY2019Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
609000
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
479000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6169645
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6169645
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5669645
CY2019Q1 us-gaap Restricted Cash
RestrictedCash
50000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
143000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q1 bstg Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-23000
CY2018Q1 bstg Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
0
CY2019Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0
CY2018Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
300000
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1355
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5269268
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5897350
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
84000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
53000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
11000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
11000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
163000
CY2019Q1 bstg Interest Payable On Minimum Future Lease Payments Relating To Operating Lease
InterestPayableOnMinimumFutureLeasePaymentsRelatingToOperatingLease
-20000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
143000
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P180D
CY2019Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases laboratory and office space, and certain equipment
CY2019Q1 us-gaap Lessee Operating Sublease Option To Extend
LesseeOperatingSubleaseOptionToExtend
The facility sublease with Harvard Bioscience currently runs through May 31, 2020 and automatically extends annually unless the Company or Harvard Bioscience provides a notice of termination within one hundred and eighty days prior to May 31 of each year
CY2019Q1 bstg Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
23000
CY2018Q1 bstg Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
0
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2019Q1 bstg Decrease In Deferred Tax Assets Valuation Allowance
DecreaseInDeferredTaxAssetsValuationAllowance
0
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
293000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75000
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
98000
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
7000
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
105000
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
CY2019Q1 us-gaap Share Price
SharePrice
2.35
CY2018Q4 us-gaap Share Price
SharePrice
2.06
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
92212
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
92212
CY2018Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
51000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000000
CY2018Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.60
CY2018Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3600000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3400000
CY2018Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
250000
CY2018Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.60
CY2018Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
900000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
800000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
293000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1971000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1337000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3423000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1545000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1044000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
51000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
3048000
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Biostage, Inc.
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001563665
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
BSTG
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6672223
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 bstg Stock Issuance During The Period Value Ofcommon Stock From Execise Of Warrants
StockIssuanceDuringThePeriodValueOfcommonStockFromExeciseOfWarrants
1000000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
2034000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1480000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2034000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1480000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
107000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-65000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1545000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1115000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1355000

Files In Submission

Name View Source Status
0001144204-19-025987-index-headers.html Edgar Link pending
0001144204-19-025987-index.html Edgar Link pending
0001144204-19-025987.txt Edgar Link pending
0001144204-19-025987-xbrl.zip Edgar Link pending
bstg-20190331.xml Edgar Link completed
bstg-20190331.xsd Edgar Link pending
bstg-20190331_cal.xml Edgar Link unprocessable
bstg-20190331_def.xml Edgar Link unprocessable
bstg-20190331_lab.xml Edgar Link unprocessable
bstg-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv520740_10q.htm Edgar Link pending
tv520740_ex31-1.htm Edgar Link pending
tv520740_ex31-2.htm Edgar Link pending
tv520740_ex32-1.htm Edgar Link pending
tv520740_ex32-2.htm Edgar Link pending